[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535241":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":130,"collaborators":134,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":140,"sex":145,"minAge":146,"maxAge":10,"enrollmentInfo":147,"targetDuration":150,"studyType":151,"phases":10,"briefSummary":152,"conditions":153,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},{"fullName":5,"class":6},"Nova Scotia Health Authority","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"RASTA AF Cohort",null,"Patients who meet the inclusion criteria for RASTA-AF, and do not meet any of the exclusion criteria but decline or are not approached for participation in the RCT will be asked to participate.",[13],{"name":14,"affiliation":15,"role":16},"Ratika Parkash, MD, FRCPC","Nova Scotia Health","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Laura Hamilton, BSC, MAHSR","CONTACT","902 473-7226","laura.hamilton@nshealth.ca",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Karen Giddens","902 237-5551","karen.giddens@nshealth.ca",[28,46,62,76,89,102,116],{"facility":29,"status":30,"city":31,"state":32,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Foothills Hospital","RECRUITING","Calgary","Alberta","Canada","CA",{"type":36,"coordinates":37},"Point",[38,39],-114.08529,51.05011,{"lat":39,"lon":38},[42,44],{"name":43,"role":20,"phone":10,"phoneExt":10,"email":10},"Jennifer McKeage",{"name":45,"role":16,"phone":10,"phoneExt":10,"email":10},"Stephen Wilton, MD, FRCPC",{"facility":47,"status":30,"city":48,"state":49,"zip":50,"country":33,"countryCode":34,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"QEIIHSC","Halifax","Nova Scotia","B3H 3A7",{"type":36,"coordinates":52},[53,54],-63.57688,44.64269,{"lat":54,"lon":53},[57,61],{"name":58,"role":20,"phone":59,"phoneExt":10,"email":60},"Laura Hamilton","902-473-7226","laura.hamiton@nshealth.ca",{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"facility":63,"status":30,"city":64,"state":65,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"London Health Sciences Centre","London","Ontario",{"type":36,"coordinates":67},[68,69],-81.23304,42.98339,{"lat":69,"lon":68},[72,74],{"name":73,"role":20,"phone":10,"phoneExt":10,"email":10},"Keza Motlana",{"name":75,"role":16,"phone":10,"phoneExt":10,"email":10},"Allan Skanes, MD, FRCP(C)",{"facility":77,"status":30,"city":78,"state":65,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"University of Ottawa Heart Institute","Ottawa",{"type":36,"coordinates":80},[81,82],-75.69812,45.41117,{"lat":82,"lon":81},[85,87],{"name":86,"role":20,"phone":10,"phoneExt":10,"email":10},"Tammy Knight",{"name":88,"role":16,"phone":10,"phoneExt":10,"email":10},"David Birnie, MD, FRCP(C)",{"facility":90,"status":30,"city":91,"state":65,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Sunnybrook Hospital","Toronto",{"type":36,"coordinates":93},[94,95],-79.39864,43.70643,{"lat":95,"lon":94},[98,100],{"name":99,"role":20,"phone":10,"phoneExt":10,"email":10},"Ambreen Syeda",{"name":101,"role":16,"phone":10,"phoneExt":10,"email":10},"Eugene Crystal, MD, FRCP(C)",{"facility":103,"status":30,"city":104,"state":105,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Montreal Heart Institute","Montreal","Quebec",{"type":36,"coordinates":107},[108,109],-73.58781,45.50884,{"lat":109,"lon":108},[112,114],{"name":113,"role":20,"phone":10,"phoneExt":10,"email":10},"Caroline Girard",{"name":115,"role":16,"phone":10,"phoneExt":10,"email":10},"Lena Rivard, MD, FRCP (C)",{"facility":117,"status":30,"city":118,"state":119,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Regina General Hospital","Regina","Saskatchewan",{"type":36,"coordinates":121},[122,123],-104.6178,50.45008,{"lat":123,"lon":122},[126,128],{"name":127,"role":20,"phone":10,"phoneExt":10,"email":10},"Maria Gagarinova",{"name":129,"role":16,"phone":10,"phoneExt":10,"email":10},"Omar Sultan, MD, FRCP(C)",{"type":131,"investigatorFullName":132,"investigatorTitle":133,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ratika Parkash","Physician",[135],{"name":136,"class":137},"Nova Scotia Health Research Fund","UNKNOWN","100535241","reversal-of-atrial-substrate-to-prevent-atrial-fibrillation-cohort-study-100535241",false,"NCT06249269","Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study","RASTA-Cohort","Inclusion Criteria:\n\n* symptomatic AF (CCS-SAF ≥2),\n* paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and either: i) BMI ≥ 30 or, ii) at least two of the following: BMI\\>27, BP\\>140\u002F90 mmHg or history of hypertension, Diabetes, Heart failure (prior heart failure admission or LVEF\\\u003C40%), Age ≥ 65 years, Prior stroke\u002FTIA, Current smoker, Excessive alcohol use {For women: 10 or more drinks\u002Fweek, more than 2 drinks a day (most days). For men: 15 or more drinks\u002Fweek, more than 3 drinks a day (most days)}, and iii) declined or were not approached for participation in the main study. Eligible patients must have received catheter ablation for AF during the same timeline of the RASTA-AF Mian Study (November 1st, 2019 to December 31st, 2025).\n\nExclusion Criteria:\n\n* permanent AF (AF lasting \\> 3 years),\n* prior catheter ablation for AF\n* New York Heart Association Class IV heart failure\n* participation in a cardiac rehabilitation program within the last year,\n* currently performing exercise training \\>150 minutes\u002Fweek of moderate to vigorous physical activity,\n* unable to exercise,\n* unable to give informed consent,\n* other noncardiovascular medical condition making 1 year survival unlikely\n* less than 18 years of age","ALL","18 Years",{"count":148,"type":149},198,"ESTIMATED","2 Years","OBSERVATIONAL","Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF.\n\nThis study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.",[154],"Atrial Fibrillation, Paroxysmal or Persistent","2025-11-25",{"date":157,"type":158},"2025-12-02","ACTUAL",{"date":160,"type":158},"2024-05-01",{"date":162,"type":149},"2027-03",{"name":132,"class":6},7]